Eli Lilly’s $3.8 billion acquisition of AtaiBeckley signals strong backing for psychedelic therapeutics

Novartis and Roche kicked off the second‑quarter earnings season, with other majors such as AstraZeneca, GSK and Biogen slated to follow. The earnings wave highlights continued revenue growth across the sector.

Eli Lilly announced a deal to purchase AtaiBeckley for up to $3.8 billion, a move analysts say validates psychedelics and interventional psychiatry as an emerging drug category. The transaction is viewed as a strategic boost for the fledgling psychedelic therapeutics space.

Meanwhile, the FDA is revisiting its policy of publishing complete response letters in real time, creating a minor regulatory stir. At the same time, the market remains active with a series of biotech IPOs slated for the second half of the year.